Rodrigues Daniela, Longatto-Filho Adhemar, Martins Sandra F
Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus of Gualtar, 4710-057 Braga, Portugal; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Campus of Gualtar, 4710-057 Braga, Portugal.
Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus of Gualtar, 4710-057 Braga, Portugal; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Campus of Gualtar, 4710-057 Braga, Portugal; Laboratory of Medical Investigation (LIM) 14, Faculty of Medicine, University of São Paulo, 01246-903 São Paulo, SP, Brazil; Molecular Oncology Research Centre, 14784-400 Barretos, SP, Brazil.
Biomed Res Int. 2016;2016:6896024. doi: 10.1155/2016/6896024. Epub 2016 Aug 1.
Colorectal cancer (CRC) is one of the most frequent cancers and is a leading cause of cancer death worldwide. Treatments used for CRC may include some combination of surgery, radiation therapy, chemotherapy, and targeted therapy. The current standard drugs used in chemotherapy are 5-fluorouracil and leucovorin in combination with irinotecan and/or oxaliplatin. Most recently, biologic agents have been proven to have therapeutic benefits in metastatic CRC alone or in association with standard chemotherapy. However, patients present different treatment responses, in terms of efficacy and toxicity; therefore, it is important to identify biological markers that can predict the response to therapy and help select patients that would benefit from specific regimens. In this paper, authors review CRC genetic markers that could be useful in predicting the sensitivity/resistance to chemotherapy.
结直肠癌（CRC）是最常见的癌症之一，也是全球癌症死亡的主要原因。用于CRC的治疗方法可能包括手术、放射治疗、化疗和靶向治疗的某种组合。目前化疗中使用的标准药物是5-氟尿嘧啶和亚叶酸联合伊立替康和/或奥沙利铂。最近，生物制剂已被证明单独或与标准化疗联合使用对转移性CRC具有治疗益处。然而，患者在疗效和毒性方面表现出不同的治疗反应；因此，识别能够预测治疗反应并帮助选择可能从特定治疗方案中获益的患者的生物标志物非常重要。在本文中，作者综述了可能有助于预测对化疗敏感性/耐药性的CRC基因标志物。
